192 related articles for article (PubMed ID: 34956230)
1. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
2. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
4. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.
Hussein BA; Kristenson L; Pesce S; Wöhr A; Tian Y; Hallner A; Brune M; Hellstrand K; Tang KW; Bernson E; Thorén FB
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648262
[TBL] [Abstract][Full Text] [Related]
5. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
Hallner A; Bernson E; Hussein BA; Ewald Sander F; Brune M; Aurelius J; Martner A; Hellstrand K; Thorén FB
Blood; 2019 Mar; 133(13):1479-1488. PubMed ID: 30647027
[TBL] [Abstract][Full Text] [Related]
6. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.
Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031
[TBL] [Abstract][Full Text] [Related]
7. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.
Bernson E; Hallner A; Sander FE; Nicklasson M; Nilsson MS; Christenson K; Aydin E; Liljeqvist JÅ; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Cancer Immunol Res; 2018 Sep; 6(9):1110-1119. PubMed ID: 29980537
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.
Cuapio A; Post M; Cerny-Reiterer S; Gleixner KV; Stefanzl G; Basilio J; Herndlhofer S; Sperr WR; Brons NH; Casanova E; Zimmer J; Valent P; Hofer E
Oncotarget; 2016 Jul; 7(29):46466-46481. PubMed ID: 27341131
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
12. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
13. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia.
Yang L; Feng Y; Wang S; Jiang S; Tao L; Li J; Wang X
Int Immunopharmacol; 2021 Oct; 99():107965. PubMed ID: 34273636
[TBL] [Abstract][Full Text] [Related]
14. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
15. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
[TBL] [Abstract][Full Text] [Related]
16. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
17. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
18. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
Martner A; Rydström A; Riise RE; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB
Oncoimmunology; 2016; 5(1):e1041701. PubMed ID: 26942055
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
20. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A
J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
